• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infections with the 2009 H1N1 influenza virus among hematopoietic SCT recipients: a single center experience

tetano

Editor, Senior Moderator
Bone Marrow Transplant. 2011 Jan 17. [Epub ahead of print]
Infections with the 2009 H1N1 influenza virus among hematopoietic SCT recipients: a single center experience.

Rihani R, Hayajneh W, Sultan I, Ghatasheh L, Abdel-Rahman F, Hussein N, Hussein A, Al-Zaben A, Sarhan M, Saad M.

Bone Marrow and Stem Cell Transplantation program, King Hussein Cancer Center (KHCC), Amman, Jordan.
Abstract

We retrospectively reviewed medical records of 39 hematopoietic SCT (HSCT) recipients who presented at our hospital between 1 October 2009 and 31 January 2010 with the 2009 H1N1 influenza infection. The median age at presentation was 13.8 years (range: 3.3-56.9), infections developed at a median of 585 days (range: 0-2316) post transplant, the majority (n=27, 69%) occurred in allogeneic HSCT recipients, 12 (31%) patients were on immunosuppressive therapy and 12 (31%) had GVHD. Lower airway disease was present in 8 patients (21%). In total, 15 patients (39%) were hospitalized with a median duration of 4.5 days (range: 3-27 days) and 3 (8%) required mechanical ventilation; 2 of whom died.Bone Marrow Transplantation advance online publication, 17 January 2011; doi:10.1038/bmt.2010.329.

PMID: 21243021 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/21243021
 
Back
Top Bottom